Carolyn Lou1, Nandita Mitra1, Bradley Wubbenhorst2, Kurt D'Andrea2, Ole Hoffstad1, Brian S Kim3, Albert Yan4, Andrea L Zaenglein5, Zelma Chiesa Fuxench6, Katherine L Nathanson2, David J Margolis7. 1. Department of Biostatistics, Epidemiology and Informatics, Perlman School of Medicine, Philadelphia, Pennsylvania. 2. Department of Medicine, Division of Translational Medicine and Human Genetics, Perlman School of Medicine, Philadelphia, Pennsylvania. 3. Washington University School of Medicine, St Louis, Missouri. 4. Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. 5. Departments of Dermatology and Pediatrics, Pennsylvania State University/Hershey Medical Center, Hershey, Pennsylvania. 6. Department of Dermatology, Perlman School of Medicine, Philadelphia, Pennsylvania. 7. Department of Biostatistics, Epidemiology and Informatics, Perlman School of Medicine, Philadelphia, Pennsylvania; Department of Dermatology, Perlman School of Medicine, Philadelphia, Pennsylvania. Electronic address: margo@pennmedicine.upenn.edu.
Abstract
BACKGROUND: Atopic dermatitis (AD) is a common chronic relapsing skin disease. Genetic variants have been associated with skin barrier function and immune regulation. Thymic stromal lymphopoietin (TSLP), an immune regulator, has been previously associated with AD. OBJECTIVE: To fine map TSLP and evaluate associations with the onset and persistence of AD. METHODS: TSLP variation was determined using targeted massively parallel sequencing in a longitudinal cohort of children with AD. Evaluations included linkage disequilibrium and the persistence of AD for as many as 10 years of follow-up. The association between the presence of AD and rs1898671 variation was evaluated in a second independent cohort. RESULTS: The minor variant frequency for rs1898671 was 23.5% (95% CI, 21.4%-25.8%). This variant was not in linkage disequilibrium with other TSLP variants in the longitudinal cohort (n = 741). White children with AD were less likely to have rs1898671 variant (odds ratio [OR], 1.41; 95% CI, 1.20-1.66) than Genome Aggregation Database controls. Children with AD and the rs1898671 variant during follow-up were more likely to have remission than children who were wild type for rs1898671 (OR, 1.56; 95% CI, 1.26-1.91). In the second cohort (n = 585), the rs1898671 variant was less prevalent in those with AD than those without. The protective effect was greater in rs1898671 heterozygotes (OR, 1.91; 95% CI, 1.34-2.75) than homozygotes (OR, 1.28; 95% CI, 0.61-2.70). CONCLUSION: TSLP and specifically rs1898671 are important in the pathogenesis of AD and could represent a potential clinical target for the development of therapies to treat individuals with AD.
BACKGROUND:Atopic dermatitis (AD) is a common chronic relapsing skin disease. Genetic variants have been associated with skin barrier function and immune regulation. Thymic stromal lymphopoietin (TSLP), an immune regulator, has been previously associated with AD. OBJECTIVE: To fine map TSLP and evaluate associations with the onset and persistence of AD. METHODS:TSLP variation was determined using targeted massively parallel sequencing in a longitudinal cohort of children with AD. Evaluations included linkage disequilibrium and the persistence of AD for as many as 10 years of follow-up. The association between the presence of AD and rs1898671 variation was evaluated in a second independent cohort. RESULTS: The minor variant frequency for rs1898671 was 23.5% (95% CI, 21.4%-25.8%). This variant was not in linkage disequilibrium with other TSLP variants in the longitudinal cohort (n = 741). White children with AD were less likely to have rs1898671 variant (odds ratio [OR], 1.41; 95% CI, 1.20-1.66) than Genome Aggregation Database controls. Children with AD and the rs1898671 variant during follow-up were more likely to have remission than children who were wild type for rs1898671 (OR, 1.56; 95% CI, 1.26-1.91). In the second cohort (n = 585), the rs1898671 variant was less prevalent in those with AD than those without. The protective effect was greater in rs1898671 heterozygotes (OR, 1.91; 95% CI, 1.34-2.75) than homozygotes (OR, 1.28; 95% CI, 0.61-2.70). CONCLUSION:TSLP and specifically rs1898671 are important in the pathogenesis of AD and could represent a potential clinical target for the development of therapies to treat individuals with AD.
Authors: Mei Li; Pierre Hener; Zhikun Zhang; Krishna P Ganti; Daniel Metzger; Pierre Chambon Journal: J Invest Dermatol Date: 2008-07-24 Impact factor: 8.551
Authors: David J Margolis; Nandita Mitra; Heather Gochnauer; Bradley Wubbenhorst; Kurt D'Andrea; Adam Kraya; Ole Hoffstad; Jayanta Gupta; Brian Kim; Albert Yan; Zelma Chiesa Fuxench; Katherine L Nathanson Journal: J Invest Dermatol Date: 2018-02-08 Impact factor: 8.551
Authors: Charles N Ellis; Lynn A Drake; Mary M Prendergast; William Abramovits; Mark Boguniewicz; C Ralph Daniel; Mark Lebwohl; Seth R Stevens; Diane L Whitaker-Worth; J Wang Cheng; Kuo B Tong Journal: J Am Acad Dermatol Date: 2002-03 Impact factor: 11.527
Authors: Mario Noti; Elia D Tait Wojno; Brian S Kim; Mark C Siracusa; Paul R Giacomin; Meera G Nair; Alain J Benitez; Kathryn R Ruymann; Amanda B Muir; David A Hill; Kudakwashe R Chikwava; Amin E Moghaddam; Quentin J Sattentau; Aneesh Alex; Chao Zhou; Jennifer H Yearley; Paul Menard-Katcher; Masato Kubo; Kazushige Obata-Ninomiya; Hajime Karasuyama; Michael R Comeau; Terri Brown-Whitehorn; Rene de Waal Malefyt; Patrick M Sleiman; Hakon Hakonarson; Antonella Cianferoni; Gary W Falk; Mei-Lun Wang; Jonathan M Spergel; David Artis Journal: Nat Med Date: 2013-07-21 Impact factor: 53.440
Authors: Vassili Soumelis; Pedro A Reche; Holger Kanzler; Wei Yuan; Gina Edward; Bernhart Homey; Michel Gilliet; Steve Ho; Svetlana Antonenko; Annti Lauerma; Kathleen Smith; Daniel Gorman; Sandra Zurawski; Jon Abrams; Satish Menon; Terri McClanahan; Rene de Waal-Malefyt Rd; Fernando Bazan; Robert A Kastelein; Yong-Jun Liu Journal: Nat Immunol Date: 2002-06-10 Impact factor: 25.606
Authors: David J Margolis; Nandita Mitra; Ole J Hoffstad; Brian S Kim; Dimitri S Monos; Elizabeth J Phillips Journal: J Immunol Date: 2021-08-18 Impact factor: 5.426
Authors: David J Margolis; Nandita Mitra; Brian S Kim; Jamie L Duke; Ron A Berna; Ole J Hoffstad; Jenna R Wasserman; Deborah A Ferriola; Tim L Mosbruger; Bradley S Wubbenhorst; Kathrine L Nathanson; Dimitri S Monos Journal: J Immunol Date: 2021-04-16 Impact factor: 5.422
Authors: A L Bosma; A Ascott; R Iskandar; K Farquhar; J Matthewman; M W Langendam; A Mulick; K Abuabara; H C Williams; P I Spuls; S M Langan; M A Middelkamp-Hup Journal: J Eur Acad Dermatol Venereol Date: 2022-02-25 Impact factor: 9.228